Bayer's Xarelto wins ACS nod in Europe; Mumbai hospital reportedly nixes Ranbaxy drugs;

@FiercePharma: India's Sun Pharma beats on profits, with 31% revenue hike to about $550M. More | Follow @FiercePharma

@EricPFierce: U.S. arrests 2 Pakistani men for selling controlled substances via the Internet. Interpol tracks them to London. Report | Follow @EricPFierce

> Bayer's blood thinner Xarelto won Europe's blessing for a new indication in treating patients with acute coronary syndrome, a use the FDA has so far declined to approve. Report

> A hospital in Mumbai advised doctors that certain Ranbaxy medicines would not be available there and advised doctors not to prescribe them; company officials are reportedly negotiating with the facility. Report

> The tax debates in Ireland continue, this time with talk about two Abbott Laboratories ($ABT) subsidiaries that each reported profits topping €1 billion but paid no tax. Report

> India's Sun Pharmaceutical posted a 23.4% increase in quarterly profits on a 31% hike in sales to 30.71 billion rupees, or $549 million. Report

> Turkish officials aim to boost local drug production with proposed investments in medical research and development. Report

> An AstraZeneca ($AZN) unit will unload about 3.7 million shares of the company's Indian subsidiary to meet new securities regulations that set a minimum on public shareholding. Report

Medical Device News

@FierceMedDev: Roche launches DNA kit amid applied science shake-up. Article | Follow @FierceMedDev

 @DamianFierce: In case you missed it Monday, Valeant is buying Bausch + Lomb for $8.7B. Report | Follow @DamianFierce

> Medical device firms still passing tax on to hospitals, group says. Item

> Sluggish FDA device approvals frustrate cardiologists. Report

> Paris, je stent: Fierce's 2013 EuroPCR coverage. More

> FDA sticks 'deadly' tag on Cook's stent recall. News

Biotech News

@FierceBiotech: Trending this weekend: Top 10 Biotech CEO Pay Packages of 2012. Feature | Follow @FierceBiotech

@JohnCFierce: From earlier today: AstraZeneca scoops up PhIII cardio drug in $443M Omthera buyout (did AZ pay too much?) Story | Follow @JohnCFierce

> Are biotech IPOs already getting too hot to handle? More

> Biotech gets $12M to work on amped-up herbal anti-inflammatory. Item

> Pharmaxis slashes staff after FDA red-flags cystic fibrosis treatment. Article

> Alexion snags latest 'breakthrough' coup with PhIII rare-disease drug. News

Pharma News

@FiercePharma: India's Sun Pharma beats on profits, with 31% revenue hike to about $550M. More | Follow @FiercePharma

@EricPFierce: U.S. arrests 2 Pakistani men for selling controlled substances via the Internet. Interpol tracks them to London. Report | Follow @EricPFierce

> Feds subpoena Forest Labs in Tudorza Pressair investigation. Story

> Drugmakers to reap $115B in sales as Obamacare rolls on, study finds. Report

> ISTA excluded from Medicare in $33.5M off-label settlement. Article

Pharma Manufacturing News

> India takes another step to meet looming EU API rules. Story

> FDA tracking down new outbreak tied to compounded drug. More

> U.S. holds two Pakistani men for Internet sales of controlled substances. Report

> Indian regulators unsure how to react to USFDA actions. Article

CRO News

> Parexel expands eClinical presence in China. Article

> India amps up clinical trial consent regulations. Report

> Corgenix inks cancer deal with Lilly. More

> Nordion sells off drug unit for $200M, focuses on contracting. Story

Biotech IT News

> Boehringer VP impressed by wireless pill bottle. Item

> Treato sees success for Biogen in social media buzz. Article

> Genentech asks iPad gamers to save San Fran from mutant cheese. More

> Chinese trial data hackers reportedly active again. Report

Biotech Research News

 @EmilyMFierce: Universal flu vaccine effective in preclinical studies. More | Follow @EmilyMFierce

> Stem cell cloning study contained errors. Story

> Stabilizing a gene reverses schizophrenia in mice. Report

> New study refutes Targretin claim for treatment of Alzheimer's. Article

And Finally... Does the FDA need to remove some roadblocks to new sunblock ingredients? Report

Suggested Articles

Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.

With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.